Skip to content

Clinical Study for Bupi Qingfei Decoction on Reducing Recurrent Attack of Pseudomonas aeruginosa Colonized Bronchiectasis

Clinical Study for Bupi Qingfei Decoction on Reducing Recurrent Attack of Pseudomonas aeruginosa Colonized Bronchiectasis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002573
Enrollment
Unknown
Registered
2019-09-05
Start date
2018-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis

Interventions

Sponsors

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Outpatient or inpatient patients who meet the diagnostic criteria of PA-colonized bronchiectasis; 2. Aged 18-70 years old; 3. Patients with lung-qi deficiency and phlegm-heat accumulation in TCM syndrome differentiation; 4. Patients with acute exacerbation at least once in the past year; 5. Those who are willing to follow the doctor's diagnosis and treatment arrangements and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who do not meet the above criteria for diagnosis and differentiation of TCM syndrome; 2. Pregnant or lactating women; 3. History of chronic alcoholism or drug abuse or any factors affecting compliance; 4. Low compliance during screening period; 5. Complications with cardiovascular diseases (such as acute myocardial infarction, heart failure, etc.), cerebrovascular diseases (such as cerebral infarction, cerebral hemorrhage), liver diseases (such as viral hepatitis, cirrhosis, etc.). Primary diseases such as kidney (such as glomerulonephritis, nephrotic syndrome, etc.) and hematopoietic system (such as leukemia, hematopoietic dysfunction, etc.); 6. Liver and kidney dysfunction: abnormal liver (ALT or AST) more than double the upper limit of normal value or abnormal renal function (BUN or Cr); 7. Psychiatric patients; 8. allergic constitution and allergic to this drug; 9. Hemoptysis is the main cause of bronchiectasis those who want to perform; 10. those who have participated in other clinical trials in 1 months; 11. Other situations that the researchers think are not suitable for selection.

Design outcomes

Primary

MeasureTime frame
immunoglobulin;ESR;liver and kidney function;urinary routine;Blood Routine;CRP;

Countries

China

Contacts

Public ContactMiao Qing

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

miaoqing55@sina.com+86 13910812309

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026